Defence Therapeutics Stock Probability of Future OTC Stock Price Finishing Over 0.35
| DTCFF Stock | USD 0.41 0.01 2.50% |
Defence |
Defence Therapeutics Target Price Odds to finish over 0.35
The tendency of Defence OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 0.35 in 90 days |
| 0.41 | 90 days | 0.35 | close to 99 |
Based on a normal probability distribution, the odds of Defence Therapeutics to stay above $ 0.35 in 90 days from now is close to 99 (This Defence Therapeutics probability density function shows the probability of Defence OTC Stock to fall within a particular range of prices over 90 days) . Probability of Defence Therapeutics price to stay between $ 0.35 and its current price of $0.41 at the end of the 90-day period is about 35.76 .
Assuming the 90 days horizon Defence Therapeutics has the beta coefficient that is very close to zero suggesting the returns on DOW JONES INDUSTRIAL and Defence Therapeutics do not appear to be reactive. Additionally It does not look like Defence Therapeutics' alpha can have any bearing on the current valuation. Defence Therapeutics Price Density |
| Price |
Predictive Modules for Defence Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Defence Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Defence Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Defence Therapeutics is not an exception. The market had few large corrections towards the Defence Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Defence Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Defence Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.13 |
Defence Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Defence Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Defence Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Defence Therapeutics generated a negative expected return over the last 90 days | |
| Defence Therapeutics has some characteristics of a very speculative penny stock | |
| Defence Therapeutics has high historical volatility and very poor performance | |
| Defence Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Defence Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Defence Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Defence Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Defence to invest in growth at high rates of return. When we think about Defence Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (7.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Defence Therapeutics has accumulated about 506.7 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Defence Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Defence OTC Stock often depends not only on the future outlook of the current and potential Defence Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Defence Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.6 M |
Defence Therapeutics Technical Analysis
Defence Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Defence OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Defence Therapeutics. In general, you should focus on analyzing Defence OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Defence Therapeutics Predictive Forecast Models
Defence Therapeutics' time-series forecasting models is one of many Defence Therapeutics' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Defence Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Defence Therapeutics
Checking the ongoing alerts about Defence Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Defence Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Defence Therapeutics generated a negative expected return over the last 90 days | |
| Defence Therapeutics has some characteristics of a very speculative penny stock | |
| Defence Therapeutics has high historical volatility and very poor performance | |
| Defence Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Defence Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Defence Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Defence Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Defence to invest in growth at high rates of return. When we think about Defence Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (7.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Defence Therapeutics has accumulated about 506.7 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.